Epigenetic drugs: More than meets the eye.

Epigenetics

a Cancer Epigenetics and Biology Program (PEBC) , Bellvitge Biomedical Research Institute (IDIBELL), Barcelona , Catalonia , Spain.

Published: May 2017

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5453189PMC
http://dx.doi.org/10.1080/15592294.2017.1322881DOI Listing

Publication Analysis

Top Keywords

epigenetic drugs
4
drugs meets
4
meets eye
4
epigenetic
1
meets
1
eye
1

Similar Publications

Redirecting glucose flux during in vitro expansion generates epigenetically and metabolically superior T cells for cancer immunotherapy.

Cell Metab

January 2025

Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA; Tumor Microenvironment Center, UPMC Hillman Cancer Center, Pittsburgh, PA, USA; Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Electronic address:

Cellular therapies are living drugs whose efficacy depends on persistence and survival. Expansion of therapeutic T cells employs hypermetabolic culture conditions to promote T cell expansion. We show that typical in vitro expansion conditions generate metabolically and functionally impaired T cells more reliant on aerobic glycolysis than those expanding in vivo.

View Article and Find Full Text PDF

Breast cancer (BC) is the most prevalent cancer in women globally. Anti-cancer advancements have enabled the killing of BC cells through various therapies; however, cancer relapse is still a major limitation and decreases patient survival and quality of life. Epithelial-to-mesenchymal transition (EMT) is responsible for tumor relapse in several cancers.

View Article and Find Full Text PDF

Background: The accurate identification of molecular subtypes in digestive tract cancer (DTC) is crucial for making informed treatment decisions and selecting potential biomarkers. With the rapid advancement of artificial intelligence, various machine learning algorithms have been successfully applied in this field. However, the complexity and high dimensionality of the data features may lead to overlapping and ambiguous subtypes during clustering.

View Article and Find Full Text PDF

Personalized statin therapy: Targeting metabolic processes to modulate the therapeutic and adverse effects of statins.

Heliyon

January 2025

Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, Xinjiang, 830046, China.

Statins are widely used for treating lipid disorders and cardiovascular diseases. However, the therapeutic efficiency and adverse effects of statins vary among different patients, which numerous clinical and epidemiological studies have attributed to genetic polymorphisms in statin-metabolizing enzymes and transport proteins. The metabolic processes of statins are relatively complex, involving spontaneous or enzyme-catalyzed interconversion between more toxic lactone metabolites and active acid forms in the liver and bloodstream, influenced by multiple factors, including the expression levels of many metabolic enzymes and transporters.

View Article and Find Full Text PDF

Background: To date, there is no effective cure for the highly malignant brain tumor glioblastoma (GBM). GBM is the most common, aggressive central nervous system tumor (CNS). It commonly originates in glial cells such as microglia, oligodendroglia, astrocytes, or subpopulations of cancer stem cells (CSCs).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!